Surgical Management of Valvular Heart Disease in Mucopolysaccharidoses: A Review of Literature

Abstract

Mucopolysaccharidoses are extremely rare diseases that are frequently presenting with structural heart problems of the aortic and mitral valve in combination with myocardial dysfunction. In a substantial proportion, this leads to heart failure and is a leading cause of death in these patients. As this glycosaminoglycan degradation defect is associated with other conditions strongly influencing the perioperative risk and choice of surgical technique, multidisciplinary planning is crucial to improve short- and long-term outcomes. The extensive variance in clinical presentation between different impaired enzymes, and further within subgroups, calls for personalised treatment plans. Enzyme replacement therapies and bone marrow transplantation carry great potential as they may significantly abrogate the progress of the disease and as such reduce the clinical burden and improve life expectancy. Nevertheless, structural heart interventions may be required. We reviewed the existing literature of the less than 50 published cases regarding surgical management, technique, and choice of prostheses. Although improvement in therapy has shown promising results in protecting valvar tissue when initiated in infancy, concerns regarding stability of this effect and durability of biological prostheses remain.

Natural Polymers in Heart Valve Tissue Engineering: Strategies, Advances and Challenges

“…The most advanced and rapid development in cardiac surgery was recorded by the transcatheter valves, with technologies that include the design progress of valves, stents and catheter in order to give minimal surgical interventions (catheter-based devices) through an endovascular approach, without requirement of a cardiopulmonary bypass or cardioplegia [100][101][102]. There are different types of transcatheter aortic prosthesis, exemplified below [67]:…”